Yaya Capital

NeuralMed is a healthcare startup that leverages artificial intelligence to analyze unstructured data from diverse sources, creating a comprehensive and secure data matrix. The company focuses on developing innovative solutions that utilize proprietary algorithms to optimize real-time medical data for healthcare institutions. These algorithms enhance patient flow organization by criticality and support healthcare professionals in diagnosing conditions through the analysis of medical images and free-text reports. NeuralMed's technology is designed for seamless integration into existing systems, ensuring reliability and higher user adherence. By streamlining screening and decision-making processes, NeuralMed aims to improve diagnostic accuracy while reducing costs for healthcare providers.

XP Health is a health technology startup founded in 2019 by Antonio Moraes and James Wong, specializing in an AI-powered vision benefits platform. The company offers a unique approach to vision care by using machine learning and augmented reality to assist employees and their families in obtaining eyewear. XP Health's proprietary deep learning model employs facial recognition technology to recommend the most suitable designer frames, achieving an accuracy rate of 98%. The platform facilitates a virtual-first experience for users, allowing them to navigate care options such as finding in-person eye exams, taking online vision acuity tests, and accessing personalized eyewear. XP Health collaborates with organizations like Chegg, Zenefits, and Sequoia Consulting Group to provide a comprehensive vision benefits solution that can complement existing insurance plans while delivering cost-effective care.

ISA is a digital-first home healthcare provider harnessing technology to bring care directly to patients' home, providing higher quality services at a fraction of the cost. Currently, ISA offers outpatient care, lab work services and immunizations. We are aiming to be the largest non-hospital healthcare company in Latam, by providing access to affordable healthcare services for millions of people through the decentralization of care.

Endpoint Health, Inc. is a precision immunology company focused on researching and developing therapies that enhance outcomes for patients with critical and immune-driven illnesses, including sepsis, acute respiratory distress syndrome, and COVID-19. Founded in 2018 and headquartered in Palo Alto, California, with additional offices in Detroit, Livonia, and Chicago, the company aims to overcome the limitations of traditional drug development by creating precision therapies tailored to individual patient needs. Utilizing its proprietary AI-powered platform, OMNAI, Endpoint Health identifies and matches high-potential therapies to patients most likely to benefit, ensuring personalized treatment that significantly improves health outcomes. The company is committed to delivering innovative solutions that address the complexities of autoimmune and inflammatory conditions.

Klivo Health is a health technology company focused on enhancing the quality of life for individuals with chronic diseases. The company operates a patient management platform designed to empower users to manage their health effectively. By providing real-time monitoring of medical conditions and facilitating the transmission of critical health data, such as blood glucose levels, Klivo Health enables healthcare professionals to achieve improved clinical outcomes. The platform also offers users access to information regarding clinical conditions and dietary guidance. Through its innovative approach, Klivo Health aims to add life to years rather than merely extending lifespan.

Endpoint Health, Inc. is a precision immunology company focused on researching and developing therapies that enhance outcomes for patients with critical and immune-driven illnesses, including sepsis, acute respiratory distress syndrome, and COVID-19. Founded in 2018 and headquartered in Palo Alto, California, with additional offices in Detroit, Livonia, and Chicago, the company aims to overcome the limitations of traditional drug development by creating precision therapies tailored to individual patient needs. Utilizing its proprietary AI-powered platform, OMNAI, Endpoint Health identifies and matches high-potential therapies to patients most likely to benefit, ensuring personalized treatment that significantly improves health outcomes. The company is committed to delivering innovative solutions that address the complexities of autoimmune and inflammatory conditions.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.